Immunometabolic Reprogramming as a Therapeutic Platform: Integrating Systems Immunology with Precision Biopharmaceutical Engineering.

INTRODUCTION

Immunometabolism integrates energy demands, biosynthesis, redox homeostasis, and immune-cell function, yet metabolic phenotypes remain context dependent. This review conceptualizes immunometabolic reprogramming as a multiscale regulatory network connecting microenvironmental pressures, nutrient sensing, metabolic flux, metabolite-mediated regulation, immune-cell states, systems-level biomarkers, and precision therapeutic engineering.

METHODS

A structured narrative review synthesized literature published from January 2022 onward across five domains: microenvironmental metabolic control; metabolic signaling and pathway interactions; systems immunology and biomarker discovery; engineered therapeutic platforms; and translational evidence, safety, and patient stratification. Quantitative findings were retained only when their experimental context supported interpretation.

RESULTS

Oxygen, nutrient, pH, cytokine, and metabolite availability can reshape AMPK, mTOR, HIF-1α, and related signaling, thereby altering glycolytic, mitochondrial, lipid, amino-acid, and redox metabolism. These changes interact with transcriptional and epigenetic mechanisms to regulate immune-cell states. Systems-level profiling enables biomarker development, while engineered biologics, targeted delivery systems, extracellular-vesicle platforms, and metabolically conditioned immune cells offer emerging therapeutic opportunities. However, translational maturity varies substantially across interventions.

CONCLUSION

Immunometabolic reprogramming should be interpreted as a context-dependent network rather than a collection of isolated pathways. Clinical translation requires evidence-graded interventions, tissue- and dose-aware strategies, validated biomarkers, and patient stratification to distinguish established benefit from promising but unproven engineering approaches.